322 related articles for article (PubMed ID: 27254275)
41. Current treatment of dyslipidaemia: PCSK9 inhibitors and statin intolerance.
Koskinas K; Wilhelm M; Windecker S
Swiss Med Wkly; 2016; 146():w14333. PubMed ID: 27400448
[TBL] [Abstract][Full Text] [Related]
42. Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies.
Mohassel P; Mammen AL
Muscle Nerve; 2013 Oct; 48(4):477-83. PubMed ID: 23519993
[TBL] [Abstract][Full Text] [Related]
43. 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.
Chien SC; Chen PS; Huang YH; Tang SC; Li YH; Yeh HI
J Formos Med Assoc; 2019 Oct; 118(10):1385-1392. PubMed ID: 30584005
[TBL] [Abstract][Full Text] [Related]
44. Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care.
Herrett E; Williamson E; Beaumont D; Prowse D; Youssouf N; Brack K; Armitage J; Goldacre B; MacDonald T; Staa TV; Roberts I; Shakur-Still H; Smeeth L
BMJ Open; 2017 Dec; 7(12):e016604. PubMed ID: 29197834
[TBL] [Abstract][Full Text] [Related]
45. New insights into managing symptoms during statin therapy.
Robinson JG
Prog Cardiovasc Dis; 2019; 62(5):390-394. PubMed ID: 31669768
[TBL] [Abstract][Full Text] [Related]
46. Coronary artery calcium scoring in patients with statin associated muscle symptoms: Prescribing statins for those most likely to benefit.
Orringer CE; Blaha MJ; Stone NJ
J Clin Lipidol; 2021; 15(6):782-788. PubMed ID: 34688585
[TBL] [Abstract][Full Text] [Related]
47. Treatment Options for Statin-Associated Muscle Symptoms.
Laufs U; Scharnagl H; Halle M; Windler E; Endres M; März W
Dtsch Arztebl Int; 2015 Oct; 112(44):748-55. PubMed ID: 26575138
[TBL] [Abstract][Full Text] [Related]
48. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
Whayne TF
Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
[TBL] [Abstract][Full Text] [Related]
49. Management of patients with statin intolerance.
Fischer S; Julius U
Atheroscler Suppl; 2017 Nov; 30():33-37. PubMed ID: 29096858
[TBL] [Abstract][Full Text] [Related]
50. Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.
Penson PE; Mancini GBJ; Toth PP; Martin SS; Watts GF; Sahebkar A; Mikhailidis DP; Banach M;
J Cachexia Sarcopenia Muscle; 2018 Dec; 9(6):1023-1033. PubMed ID: 30311434
[TBL] [Abstract][Full Text] [Related]
51. Managing the underestimated risk of statin-associated myopathy.
Rallidis LS; Fountoulaki K; Anastasiou-Nana M
Int J Cardiol; 2012 Sep; 159(3):169-76. PubMed ID: 21813193
[TBL] [Abstract][Full Text] [Related]
52. Statin myopathy: an update.
Christopher-Stine L
Curr Opin Rheumatol; 2006 Nov; 18(6):647-53. PubMed ID: 17053514
[TBL] [Abstract][Full Text] [Related]
53. Clinical and laboratory phenotype of patients experiencing statin intolerance attributable to myalgia.
Harris LJ; Thapa R; Brown M; Pabbathi S; Childress RD; Heimberg M; Braden R; Elam MB
J Clin Lipidol; 2011; 5(4):299-307. PubMed ID: 21784376
[TBL] [Abstract][Full Text] [Related]
54. Statin Intolerance: an Overview of US and International Guidance.
Cheeley MK; Clegg K; Lockridge C; Schubert TJ; Jones LK
Curr Atheroscler Rep; 2023 Aug; 25(8):517-526. PubMed ID: 37410332
[TBL] [Abstract][Full Text] [Related]
55. Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries.
Rosenson RS; Gandra SR; McKendrick J; Dent R; Wieffer H; Cheng LI; Catapano AL; Oh P; Kees Hovingh G; Stroes ES
Cardiovasc Drugs Ther; 2017 Apr; 31(2):187-195. PubMed ID: 28466399
[TBL] [Abstract][Full Text] [Related]
56. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?
Muntean DM; Thompson PD; Catapano AL; Stasiolek M; Fabis J; Muntner P; Serban MC; Banach M
Drug Discov Today; 2017 Jan; 22(1):85-96. PubMed ID: 27634340
[TBL] [Abstract][Full Text] [Related]
57. Management Strategies for Statin-Associated Muscle Symptoms: How Useful Is Same-Statin Rechallenge?
Brennan ET; Joy TR
Can J Cardiol; 2017 May; 33(5):666-673. PubMed ID: 28449837
[TBL] [Abstract][Full Text] [Related]
58. A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.
Mitchell D; Guertin JR; Dubois A; Dubé MP; Tardif JC; Iliza AC; Fanton-Aita F; Matteau A; LeLorier J
Mol Diagn Ther; 2018 Apr; 22(2):241-254. PubMed ID: 29651791
[TBL] [Abstract][Full Text] [Related]
59. An assessment by the Statin Intolerance Panel: 2014 update.
Guyton JR; Bays HE; Grundy SM; Jacobson TA; The National Lipid Association Statin Intolerance Panel
J Clin Lipidol; 2014; 8(3 Suppl):S72-81. PubMed ID: 24793444
[TBL] [Abstract][Full Text] [Related]
60. Overcoming patient reluctance to statin intolerance.
Katamesh BE; Mickow AA; Huang L; Dougan BM; Ratrout BM; Nanda S; Vincent A
Kardiol Pol; 2024; 82(5):485-491. PubMed ID: 38712783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
